glp 1 and gas GLP-1 Receptor Agonist Services for Type 2 Diabetes Obesity Drug Development cat::Bone Health Pack Size:4-Pack 2022 Canadian Cardiovascular Society

glp 1 and gas GLP-1 Receptor Agonist Services for Type 2 Diabetes Obesity Drug Development cat::Bone Health Pack Size:4-Pack 2022 Canadian Cardiovascular Society

2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults - Canadian Journal of Cardiology

Retatrutide metabolic benefits Retatrutide produces all of the metabolic benefits seen with Mounjaro plus additional improvements that appear unique to triple agonism: Blood sugar control: HbA1c reductions of 1.3% to 2.0% at doses of 4-12 mg in type 2 diabetes Blood pressure: Systolic blood pressure reduction of up to 14.0 mmHg at the highest dose (roughly double what Mounjaro achieves) Lipids: Non-HDL cholesterol and triglyceride reductions Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia Inflammatory markers: Significant reductions in high-sensitivity C-reactive protein But the standout metabolic benefit, the one that has researchers most excited, is the effect on liver health

cat::Bone Health

Pack Size:4-Pack

Patients with a body mass index (BMI) greater than 27, especially those with weight-related comorbidities